Cargando…
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years
BACKGROUND: Advanced age and type 2 diabetes (T2D) are common in patients with nonvalvular atrial fibrillation (NVAF). We evaluated the impact of age on the effectiveness and safety of rivaroxaban versus warfarin in this population. METHODS: We analyzed electronic health record data from November 20...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666855/ https://www.ncbi.nlm.nih.gov/pubmed/36377242 http://dx.doi.org/10.1177/10760296221133083 |
_version_ | 1784831593668411392 |
---|---|
author | Coleman, Craig I. Costa, Olivia S. Brescia, Christopher W. Vardar, Burcu Abdelgawwad, Khaled Hofmeister, Lucas Sood, Nitesh |
author_facet | Coleman, Craig I. Costa, Olivia S. Brescia, Christopher W. Vardar, Burcu Abdelgawwad, Khaled Hofmeister, Lucas Sood, Nitesh |
author_sort | Coleman, Craig I. |
collection | PubMed |
description | BACKGROUND: Advanced age and type 2 diabetes (T2D) are common in patients with nonvalvular atrial fibrillation (NVAF). We evaluated the impact of age on the effectiveness and safety of rivaroxaban versus warfarin in this population. METHODS: We analyzed electronic health record data from November 2010, to December 2019 including adults with NVAF and T2D, newly started on rivaroxaban or warfarin. Propensity score-overlap weighted hazard ratios (HRs) for stroke/systemic embolism (SSE), hospitalization for major or clinically relevant nonmajor bleeding (CRNMB), vascular death, major adverse limb events (MALE), major bleeding, and intracranial hemorrhage (ICH) were calculated for older (≥80 years) and younger (<80 years) cohorts. RESULTS: We included 32 078 rivaroxaban and 83 971 warfarin users (6606 rivaroxaban and 25,335 warfarin patients were aged ≥80 years). No significant interaction for rivaroxaban versus warfarin by age was observed for any outcome, including SSE (HR = 1.05 vs 0.95), hospitalization for major or CRNMB (HR = 1.06 vs 0.90), vascular death (HR = 0.92 vs 0.90), MALE (HR = 0.80 vs 0.76), major bleeding or ICH. CONCLUSIONS: The effectiveness and safety of rivaroxaban versus warfarin remained consistent across patient age subgroups. |
format | Online Article Text |
id | pubmed-9666855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-96668552022-11-17 A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years Coleman, Craig I. Costa, Olivia S. Brescia, Christopher W. Vardar, Burcu Abdelgawwad, Khaled Hofmeister, Lucas Sood, Nitesh Clin Appl Thromb Hemost Original Manuscript BACKGROUND: Advanced age and type 2 diabetes (T2D) are common in patients with nonvalvular atrial fibrillation (NVAF). We evaluated the impact of age on the effectiveness and safety of rivaroxaban versus warfarin in this population. METHODS: We analyzed electronic health record data from November 2010, to December 2019 including adults with NVAF and T2D, newly started on rivaroxaban or warfarin. Propensity score-overlap weighted hazard ratios (HRs) for stroke/systemic embolism (SSE), hospitalization for major or clinically relevant nonmajor bleeding (CRNMB), vascular death, major adverse limb events (MALE), major bleeding, and intracranial hemorrhage (ICH) were calculated for older (≥80 years) and younger (<80 years) cohorts. RESULTS: We included 32 078 rivaroxaban and 83 971 warfarin users (6606 rivaroxaban and 25,335 warfarin patients were aged ≥80 years). No significant interaction for rivaroxaban versus warfarin by age was observed for any outcome, including SSE (HR = 1.05 vs 0.95), hospitalization for major or CRNMB (HR = 1.06 vs 0.90), vascular death (HR = 0.92 vs 0.90), MALE (HR = 0.80 vs 0.76), major bleeding or ICH. CONCLUSIONS: The effectiveness and safety of rivaroxaban versus warfarin remained consistent across patient age subgroups. SAGE Publications 2022-11-14 /pmc/articles/PMC9666855/ /pubmed/36377242 http://dx.doi.org/10.1177/10760296221133083 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Coleman, Craig I. Costa, Olivia S. Brescia, Christopher W. Vardar, Burcu Abdelgawwad, Khaled Hofmeister, Lucas Sood, Nitesh A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title | A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title_full | A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title_fullStr | A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title_full_unstemmed | A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title_short | A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial
Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years |
title_sort | riva-dm subanalysis investigating patients with nonvalvular atrial
fibrillation and type 2 diabetes aged under versus over 80 years |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666855/ https://www.ncbi.nlm.nih.gov/pubmed/36377242 http://dx.doi.org/10.1177/10760296221133083 |
work_keys_str_mv | AT colemancraigi arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT costaolivias arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT bresciachristopherw arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT vardarburcu arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT abdelgawwadkhaled arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT hofmeisterlucas arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT soodnitesh arivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT colemancraigi rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT costaolivias rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT bresciachristopherw rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT vardarburcu rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT abdelgawwadkhaled rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT hofmeisterlucas rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years AT soodnitesh rivadmsubanalysisinvestigatingpatientswithnonvalvularatrialfibrillationandtype2diabetesagedunderversusover80years |